journal article·2023-07Open access

An Automation Workflow for High‐Throughput Manufacturing and Analysis of Scaffold‐Supported 3D Tissue Arrays

Ruonan Cao, Nancy T. Li, Simon Latour, Jose L. Cadavid, Cassidy M. Tan, Ari Forman, Hartland W. Jackson, Alison P. McGuigan

Advanced Healthcare Materials· Volume 12· Issue 19

Abstract

Abstract Patient‐derived organoids have emerged as a useful tool to model tumour heterogeneity. Scaling these complex culture models while enabling stratified analysis of different cellular sub‐populations, however, remains a challenge. One strategy to enable higher throughput organoid cultures is the scaffold‐supported platform for organoid‐based tissues (SPOT). SPOT allows the generation of flat, thin, and dimensionally‐defined microtissues in both 96‐ and 384‐well plate footprints that are compatible with longitudinal image‐based readouts. SPOT is currently manufactured manually, however, limiting scalability. In this study, an automation approach to engineer tumour‐mimetic 3D microtissues in SPOT using a liquid handler is optimized and comparable within‐ and between‐sample variation to standard manual manufacturing is shown. Further, a liquid handler‐supported cell extraction protocol to support single‐cell‐based end‐point analysis using high‐throughput flow cytometry and multiplexed cytometry by time of flight is developed. As a proof‐of‐value demonstration, 3D complex tissues containing different proportions of tumour and stromal cells are generated to probe the reciprocal impact of co‐culture. It is also demonstrated that primary patient‐derived organoids can be incorporated into the pipeline to capture patient‐level tumour heterogeneity. It is envisioned that this automated 96/384‐SPOT workflow will provide opportunities for future applications in high‐throughput screening for novel personalized therapeutic targets.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Microfluidic and Bio-sensing Technologies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Biomedical Engineering University of Toronto 164 College Street Toronto ON M5S 3G9 Canada

Department of Chemical Engineering and Applied Chemistry University of Toronto 200 College Street Toronto ON M5R 3S5 Canada

Lunenfeld‐Tanenbaum Research Institute Mount Sinai Hospital 600 University Ave Toronto ON M5G 1X5 Canada

Department of Molecular Genetics University of Toronto 1 King's College Cir Toronto ON M5S 1A8 Canada

Ontario Institute of Cancer Research 661 University Ave Toronto ON M5G 0A3 Canada

Funding

Natural Sciences and Engineering Research Council of Canada · Canada First Research Excellence Fund

References (59)

Show source-provided references
1. 10.1016/j.actbio.2021.01.02310.1016/j.actbio.2021.01.023 ↗
2. 10.3389/fmolb.2019.0016010.3389/fmolb.2019.00160 ↗
3. 10.1016/j.biomaterials.2019.11974410.1016/j.biomaterials.2019.119744 ↗
4. 10.1038/nm.443810.1038/nm.4438 ↗
5. 10.1126/science.aao277410.1126/science.aao2774 ↗
6. 10.1016/j.stem.2018.09.01610.1016/j.stem.2018.09.016 ↗
7. 10.1016/j.cell.2018.11.02110.1016/j.cell.2018.11.021 ↗
8. 10.1177/247255521876684210.1177/2472555218766842 ↗
9. 10.3389/fonc.2020.0055310.3389/fonc.2020.00553 ↗
10. 10.1016/j.cell.2017.01.01810.1016/j.cell.2017.01.018 ↗
11. 10.1038/nm.397310.1038/nm.3973 ↗
12. 10.1016/j.stem.2019.10.01010.1016/j.stem.2019.10.010 ↗
13. 10.1016/j.biomaterials.2022.12141710.1016/j.biomaterials.2022.121417 ↗
14. 10.1038/s41467-018-04919-w10.1038/s41467-018-04919-w ↗
15. 10.1038/s41467-020-19058-410.1038/s41467-020-19058-4 ↗
16. 10.1039/C9LC00496C10.1039/C9LC00496C ↗
17. 10.1002/adfm.20210534910.1002/adfm.202105349 ↗
18. 10.1038/s42003-019-0305-x10.1038/s42003-019-0305-x ↗
19. 10.1038/s41598-017-18050-110.1038/s41598-017-18050-1 ↗
20. 10.1039/C7AN00806F10.1039/C7AN00806F ↗
21. 10.1016/j.biomaterials.2015.02.01210.1016/j.biomaterials.2015.02.012 ↗
22. 10.1016/j.biomaterials.2022.12188310.1016/j.biomaterials.2022.121883 ↗
23. 10.1039/C9BM02017A10.1039/C9BM02017A ↗
24. 10.1002/path.535710.1002/path.5357 ↗
25. 10.1080/2162402X.2018.143446510.1080/2162402X.2018.1434465 ↗
26. 10.3389/fbioe.2020.0104010.3389/fbioe.2020.01040 ↗
27. 10.1016/j.biomaterials.2018.05.02010.1016/j.biomaterials.2018.05.020 ↗
28. 10.1111/cas.1384310.1111/cas.13843 ↗
29. 10.1038/s41563-020-00853-910.1038/s41563-020-00853-9 ↗
30. 10.1002/adhm.20190164810.1002/adhm.201901648 ↗
31. 10.1002/adhm.20200210310.1002/adhm.202002103 ↗
32. 10.1039/D1LC00003A10.1039/D1LC00003A ↗
33. 10.1038/s41598-021-00931-110.1038/s41598-021-00931-1 ↗
34. 10.1088/1758-5090/ab47e810.1088/1758-5090/ab47e8 ↗
35. 10.1016/j.slasd.2022.06.00310.1016/j.slasd.2022.06.003 ↗
36. 10.1038/s41551-019-0497-x10.1038/s41551-019-0497-x ↗
37. 10.3389/fcell.2020.61855210.3389/fcell.2020.618552 ↗
38. 10.7554/eLife.5290410.7554/eLife.52904 ↗
39. 10.1080/07388551.2021.193271610.1080/07388551.2021.1932716 ↗
40. LeSavage B. L. · ioRxiv. · 2022
41. 10.3390/cancers1205117310.3390/cancers12051173 ↗
42. 10.1016/j.cell.2019.05.01210.1016/j.cell.2019.05.012 ↗
43. 10.1002/adhm.20220184610.1002/adhm.202201846 ↗
44. 10.1038/nmat448210.1038/nmat4482 ↗
45. Boyce M. W. · 2018
46. 10.1038/s41596-021-00603-410.1038/s41596-021-00603-4 ↗
47. 10.1038/nbt.231710.1038/nbt.2317 ↗
48. 10.1002/cyto.a.2207510.1002/cyto.a.22075 ↗
49. 10.1038/s41467-019-09128-710.1038/s41467-019-09128-7 ↗
50. 10.1016/j.bbrc.2010.11.04010.1016/j.bbrc.2010.11.040 ↗
51. 10.1038/s41580-020-0237-910.1038/s41580-020-0237-9 ↗
52. 10.1007/s00418-008-0443-610.1007/s00418-008-0443-6 ↗
53. 10.1016/j.bej.2022.10871310.1016/j.bej.2022.108713 ↗
54. 10.1038/s41467-022-28788-610.1038/s41467-022-28788-6 ↗
55. 10.1002/adhm.20190097910.1002/adhm.201900979 ↗
56. 10.1038/s41467-022-29279-410.1038/s41467-022-29279-4 ↗
57. 10.1007/978-1-4939-2519-3_810.1007/978-1-4939-2519-3_8 ↗
58. 10.1002/adfm.20210534910.1002/adfm.202105349 ↗
59. 10.1002/cyto.a.2392610.1002/cyto.a.23926 ↗